Gastrointestinal Tolerance and Safety of an Infant Formula Containing Prebiotics, Probiotics and Postbiotics.

Not Applicable

Completed

• Conditions: Gastrointestinal Tolerance
• Interventions: Other: Infant formula containing prebiotics, probiotics and postbiotics

• Registration Number: NCT04745455
• Lead Sponsor: Nutricia Research

Brief Summary

A study to investigate the gastrointestinal tolerance and safety of a new formula containing prebiotics, probiotics and postbiotics.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-01
• Study First Submitted: 2021-01-12
• Study Start: 2021-01-22
• Study First Submitted QC: 2021-02-08
• Study First Posted: 2021-02-09
• Primary Completion: 2021-07-12
• Study Completion: 2021-07-12
• Last Update Submitted: 2022-01-24
• Last Update Posted: 2022-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

1. Term infants with a gestational age at birth of ≥37 weeks + 0 days and ≤41 weeks + 6 days;
2. Singleton, healthy infants as judged by the principle investigator;
3. Infants with age at screening ≥2 weeks (14 days) and ≤ 12 weeks (84 days)
4. Infants who are fully formula fed for at least 1 week prior to screening and whose parents have autonomously decided to fully formula feed, i.e. not to breastfeed or have ended breastfeeding, and who are intending to fully formula feed;
5. Written informed consent from the parent(s) and/or legally acceptable representative(s), aged ≥ 18 years.

Exclusion Criteria

1. Infants who require to be fed a special diet other than standard cow's milk-based infant formula;

2. Infants known to have or suspected to have cow's milk protein allergy, lactose intolerance, or galactosaemia including history of any other allergic manifestations or known allergy to any of the study product ingredients;

3. Infants with known or suspected congenital diseases or malformations which could interfere with the study or its outcome parameters, such as but not limited to: GI malformations, congenital metabolic disorders, severe congenital cardiac disorders, immunodeficiency or major surgery, as per the clinical judgment of the Investigator;

4. Infants diagnosed with a gastrointestinal infection within 4 weeks prior to screening;

5. Infants with current or previous illnesses/conditions or interventions which could interfere with the study or its outcome parameters (e.g. diarrhea requiring treatment, constipation requiring treatment, regurgitation requiring treatment, dental/medical procedures which may impact oral feeding), as per the clinical judgment of the Investigator;

6. Received any of the following products/medication prior to screening: systemic antibiotics, prokinetics, proton pump inhibitors, prebiotic supplements, probiotic supplements, complementary feeding/weaning within 4 weeks prior to screening;

7. Incapability of infants' parents to comply with study protocol as per the judgment of the Investigator (e.g. fluency in local language, access to laptop/smartphone devices and internet connection required for data collection);

8. Infants with previous, current or intended participation in any other clinical study involving investigational or marketed products concomitantly or prior to study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cow's milk based infant formula containing prebiotics, probiotics and postbiotics	Infant formula containing prebiotics, probiotics and postbiotics	-

Primary Outcome Measures

Name	Time	Method
Gastrointestinal tolerance	Day 28	A 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress.

Secondary Outcome Measures

Name	Time	Method
Stool frequency	Day 28	Parent reported daily number of stools
Stool consistency	Day 28	Parent reported daily stool consistency using stool scales with categories 1; watery, 2; loose, 3; formed, 4; hard
Incidence, frequency, and severity of (S)AEs, and relatedness to study product of (Serious) Adverse Events.	Through study completion, an average of one month	(S)AE collection

Trial Locations

Locations (3)

Poliklinika Ginekologiczno-Poloznicza Sp. Z.O.O Sp.K; 🇵🇱 Białystok, Poland

Izabela Tarczoń Przylądek Zdrowia Specjalistyczne Poradnie Medyczne; 🇵🇱 Kraków, Poland

NZLA Michalkowice Jarosz i partnerzy Spolka; 🇵🇱 Siemianowice-Slaskie, Poland